HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cycloheximide facilitates the identification of aberrant transcripts resulting from a novel splice-site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa.

Abstract
Patients with generalized atrophic benign epidermolysis bullosa often show decreased expression of type XVII collagen, a transmembrane hemidesmosomal protein encoded by COL17A1. This report documents a novel splice-site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa, and applies a new methodology to define and characterize the resulting mRNA splice variants. Mutational analysis of COL17A1 identified a maternally inherited G-to-T transversion at the -1 position of exon 32. This acceptor splice-site mutation led to the formation of aberrant transcripts present at extremely low levels. Based on our recent finding that cycloheximide stabilized mutant COL17A1 transcripts in keratinocytes homozygous for a frameshift mutation, the effects of the splice-site mutation on splicing of COL17A1 transcripts were determined using reverse transcriptase polymerase chain reaction of total RNA from keratinocytes incubated for 2.5 h in the presence or absence of 10 microg cycloheximide per ml. Using this approach, an abnormally spliced transcript was identified that contains an extra 264 bases upstream from exon 32, resulting in a premature termination codon 27 bp downstream from the cryptic splice site. Three other splice variants, including one derived from the skipping of exon 32, were also identified. These results indicate the usefulness of cycloheximide treatment in evaluating the abnormal processing of mRNA due to splice-site mutations, because: (i) aberrant splicing often generates a premature termination codon, (ii) transcripts with premature termination codons can occur at low or undetectable levels due to nonsense-mediated mRNA decay, and (iii) the levels of these transcripts can be increased by cycloheximide.
AuthorsT N Darling, C Yee, B Koh, J A McGrath, J W Bauer, J Uitto, H Hintner, K B Yancey
JournalThe Journal of investigative dermatology (J Invest Dermatol) Vol. 110 Issue 2 Pg. 165-9 (Feb 1998) ISSN: 0022-202X [Print] United States
PMID9457913 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Autoantigens
  • Carrier Proteins
  • Cytoskeletal Proteins
  • DST protein, human
  • Dystonin
  • Nerve Tissue Proteins
  • Non-Fibrillar Collagens
  • RNA, Messenger
  • collagen type XVII
  • Collagen
  • Cycloheximide
Topics
  • Adult
  • Atrophy
  • Autoantigens (genetics, metabolism)
  • Carrier Proteins
  • Collagen (genetics, metabolism)
  • Cycloheximide (pharmacology)
  • Cytoskeletal Proteins
  • Dystonin
  • Epidermolysis Bullosa (genetics, pathology)
  • Humans
  • Keratinocytes (drug effects, physiology)
  • Male
  • Mutation (genetics)
  • Nerve Tissue Proteins
  • Non-Fibrillar Collagens
  • RNA Splicing (physiology)
  • RNA, Messenger (metabolism)
  • Transcription, Genetic (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: